Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8908408 | 0.84 | CCR3 (0.63) | ACHEHRH3ABL1RIN1 | |
| SCHEMBL13596996 | 0.82 | MEN1 (0.57) | MEN1ALDH1A1CYP2D6RAB9AKMT2A | |
| SCHEMBL13596997 | 0.82 | KCNH2 (0.56) | ALDH1A1ACHEHRH3ABL1RIN1 | |
| SCHEMBL4789907 | 0.80 | CCR3 (0.61) | ACHEHRH3ABL1RIN1 | |
| SCHEMBL27883986 | 0.79 | ACHE (0.55) | ACHEBACE1HRH3 | |
| SCHEMBL12044684 | 0.79 | KCNH2 (0.61) | ACHEHRH3ABL1RIN1 | |
| SCHEMBL12040802 | 0.79 | KCNH2 (0.61) | ACHEHRH3ABL1RIN1 | |
| SCHEMBL9407055 | 0.78 | ESR1 (0.55) | ALDH1A1MAOBACHEHRH3 | |
| SCHEMBL9407048 | 0.78 | ESR1 (0.55) | ALDH1A1MAOBACHEHRH3 | |
| SCHEMBL6975680 | 0.77 | HRH3 (0.73) | ALDH1A1ACHEBACE1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | TOPOTARGET SWITZERLAND SA (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | TOPOTARGET SWITZERLAND SA (CH) | 2009-12-31 | — | — | US | disclosed |
| US-7276524-B2 | Pyridyl alkane acid amides as cytostatics and immunosuppressives | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-7276524-B2 | Pyridyl alkane acid amides as cytostatics and immunosuppressives | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | ASTELLAS PHARMA GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | ASTELLAS PHARMA GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-7241745-B2 | Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives | ASTELLAS PHARMA GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241745-B2 | Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives | ASTELLAS PHARMA GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | BIEDERMANN ELFI | 2007-06-21 | — | — | US | disclosed |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | BIEDERMANN ELFI | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | NFATC1, PDCD1, ACIN1 | MEN1 2546/4885ALDH1A1 690/4885CYP2D6 1794/4885 |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | ALK, TYMP, PDCD1 | MEN1 1464/4885ALDH1A1 266/4885CYP2D6 434/4885 |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | NAMPT, NNMT, NQO2 | MEN1 3901/4885ALDH1A1 1237/4885CYP2D6 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.